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Abstract
Control of intracellular calcium concentrations ([Ca2+]i) is essential for neuronal function, and the
plasma membrane Ca2+-ATPase (PMCA) is crucial for the maintenance of low [Ca2+]i. We
previously reported on loss of PMCA activity in brain synaptic membranes during aging.
Gangliosides are known to modulate Ca2+ homeostasis and signal transduction in neurons. In the
present study, we observed age-related changes in the ganglioside composition of synaptic plasma
membranes. This led us to hypothesize that alterations in ganglioside species might contribute to
the age-associated loss of PMCA activity. To probe the relationship between changes in
endogenous ganglioside content or composition and PMCA activity in membranes of cortical
neurons, we induced depletion of gangliosides by treating neurons with D-threo-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (D-PDMP). This caused a marked decrease in the
activity of PMCA, which suggested a direct correlation between ganglioside content and PMCA
activity. Neurons treated with neuraminidase exhibited an increase in GM1 content, a loss in poly-
sialoganglioside content, and a decrease in PMCA activity that was greater than that produced by
D-PDMP treatment. Thus, it appeared that poly-sialogangliosides had a stimulatory effect whereas
mono-sialogangliosides had the opposite effect. Our observations add support to previous reports
of PMCA regulation by gangliosides by demonstrating that manipulations of endogenous
ganglioside content and species affect the activity of PMCA in neuronal membranes. Furthermore,
our studies suggest that age-associated loss in PMCA activity may result in part from changes in
the lipid environment of this Ca2+ transporter.
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1. Introduction
Precise regulation of free intracellular Ca2+ concentrations ([Ca2+]i) in neurons is highly
dynamic and serves as the basis for a vast array of signaling activities that are essential for
neuronal viability and the integrity of the entire nervous system. Neurons express multiple
systems that allow for rapid, transient Ca2+ pulses to initiate either short or long-term
signaling events and to terminate equally rapidly the Ca2+-mediated signals by returning
[Ca2+]i to normal resting levels. The extrusion of intracellular Ca2+ across the plasma
membrane takes place against a 10,000-fold gradient of this ion [1, 2]. Two integral
membrane proteins mediate the extrusion of Ca2+, the plasma membrane Ca2+ - ATPase
(PMCA) and the Na+/Ca2+ exchanger (NCX). The PMCA is a high affinity but low capacity
system for pumping Ca2+ to the extracellular medium [3–5], while the NCX is a low
affinity, high capacity antiporter. The PMCA is responsible for the fine-tuning of [Ca2+]i
and the maintenance of low resting [Ca2+]i [3–5].
The aging process in brain is accompanied by increases in overall Ca2+ content in brain
neurons and synaptic terminals and a slower clearance of intracellular Ca2+ from nerve
endings following a depolarizing stimulus [6, 7]. Previously, we reported that the activity of
PMCA in synaptic plasma membranes (SPMs) progressively decreases with age [8, 9] and
suggested that this loss in activity may contribute to the aberrant cellular Ca2+ overload
observed in aging neurons.
The PMCA is an integral membrane protein with ten transmembrane domains [10]. The
activity of this enzyme is regulated by multiple factors, including calmodulin (CaM)
binding, proteolysis, protein kinases, and acidic phospholipids in the membrane environment
of the protein [10, 11]. In addition to the modulation of the enzyme by acidic phospholipids
residing in the inner leaflet of the plasma membrane, the activity of purified and
reconstituted PMCA is also sensitive to exogenously introduced gangliosides, a class of
glycosphingolipids that reside in the outer leaflet of the plasma membrane [12, 13].
However, the influence of endogenous gangliosides on PMCA activity has not been
explored.
Gangliosides are highly enriched in the central nervous system of vertebrates. This is
particularly true in the brain where they constitute 20–25% of the outer leaflet of neuronal
membranes or 10–15% of the total lipids in nerve ending (synaptosomal) membrane
fractions [14]. Gangliosides participate in a variety of vertebrate cellular processes such as
toxin uptake and cell adhesion, growth, mobility, and differentiation [15]. In the nervous
system, gangliosides play critical roles in neuritogenesis [16, 17], synaptic transmission [18,
19], axonal regeneration, myelin stability [20], and signal transduction [21–24].
Due to their amphiphilic properties and their tendency to complex with Ca2+ ions,
gangliosides are implicated in the modulation of Ca2+ signaling and the maintenance of
cellular Ca2+ homeostasis during normal neuronal functioning [25]. Null mutant mice for
GM2/GD2 synthase are deficient in GM2, GD2, and all gangliotetraose gangliosides and
exhibit an impaired capacity for Ca2+ regulation, which supports the hypothesis that the
maintenance of Ca2+ homeostasis is a key function of complex gangliosides [26]. In rabbit
skeletal muscles, both GM3 and GM1 can induce a conformational change in the sarco/
endoplasmic reticulum Ca2+-ATPase and alter the activity of this Ca2+-sequestering enzyme
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[27]. At the plasma membrane, GM1 activates indirectly a non-voltage-gated channel, the
transient receptor potential C5 channel, by cross-linking with α5β1 integrin, thereby
activating the integrin signaling cascade and promoting Ca2+ influx and the initiation of
neurite outgrowth [28, 29]. However, unlike the information that exists with regard to
regulation of Ca2+ influx into neurons by endogenous gangliosides, there is only limited
information on the effects of endogenous gangliosides on Ca2+ efflux across the plasma
membrane [25]. This is particularly true with regard to the regulation of PMCA by
endogenous gangliosides.
In our studies of the PMCA activity in synaptic membranes, we found that the highest
activity was present in the raft domains, i.e., membrane microdomains that are highly
enriched in cholesterol and gangliosides [30]. This observation led us to hypothesize that the
content or composition of gangliosides in brain synaptic plasma membranes (SPMs) may
affect the activity of PMCA and that age-dependent alterations in endogenous ganglioside
content or composition may contribute to the age-associated loss of PMCA activity.
Therefore, our goals in these studies were: (1) to determine if endogenous SPM gangliosides
change with age; (2) to assess whether decreases in neuronal membrane content of
endogenous gangliosides lead to changes in PMCA activity; and, (3) whether alterations in
certain ganglioside species can selectively increase or decrease the PMCA activity
associated with neuronal membranes. Our results indicated that: (1) the composition of
gangliosides in rat brain SPMs was altered during aging, and (2) the activity of PMCA was
highly sensitive to alterations in both content and composition of endogenous gangliosides
in membranes of primary cortical neurons. The findings from this study indicate a novel,
CaM-independent mechanism for the regulation of PMCA activity and the modulation of
Ca2+ signaling in the CNS.
2. Materials and methods
2.1 Reagents, Antibodies and Cell Culture Media
The following reagents were purchased from Matreya LLC (Pleasant Gap, PA): D- and L-
threo-1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol•HCI (D-PDMP and L-PDMP,
respectively), purified bovine ganglioside mixture, and purified preparations of the
ammonium salts of GD1a, GD1b, and GT1b. Purified preparations of the ammonium salt of
GM1, all solvents (HPLC-grade only) used in lipid extraction or HPLC, neuraminidase
(Clostridium perfringens, type V), ouabain, thapsigargin, oligomycin, ATP, horseradish
peroxidase-coupled cholera toxin subunit B (CTXB), secondary anti-mouse and anti-rabbit
antibodies, and Phosphatase Inhibitor Cocktail 3, were obtained from Sigma-Aldrich (St.
Louis, MO). The bicinchoninic acid protein assay kit was from Pierce-Thermo Scientific
(Rockford, IL), the Protease Inhibitor Cocktail III and the high performance thin layer
chromatography (HPTLC) plates (Silica gel 60, 10 x 20 cm, Merck) were from Calbiochem-
EMD (San Diego, CA), and the purified sodium salt of GQ1b and anti-actin antibody were
from Santa Cruz Biotechnology (Santa Cruz, CA). Tris-Glycine gradient gels (8–16%) and
the serum-free Neurobasal™ cell media were purchased from Invitrogen (Carlsbad, CA), pan
PMCA antibodies (monoclonal) and antibodies to isoform-specific PMCA1-4 were obtained
from Affinity Bioreagents (Golden, CO). The polyclonal rabbit PMCA pan antibody, raised
against a 21 amino acid sequence in the middle of the PMCA, was generated by our
laboratory. All aqueous HPLC solvents were prepared in 18 mega ohm resistivity water.
2.2 Animals and isolation of brain SPMs
Fisher 344/Brown Norway hybrid (F344/BNF1) male rats at 6, 23, and 34 months of age
were obtained from the National Institute on Aging colony maintained by Harlan Industries.
All protocols were implemented in accordance with NIH guidelines and approved by the
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University of Kansas Institutional Animal Care and Use Committee. The rats were
quarantined for 2 weeks prior to their use in the studies. The rats were anesthetized by CO2
inhalation, decapitated using a guillotine, and the brains recovered quickly. The brains from
individual rats at each of the 3 ages were processed in parallel. Argon was bubbled through
all solutions immediately preceding their use. Each whole brain was homogenized and
processed for the isolation of synaptosomes by discontinuous ficoll density gradient
centrifugation [30, 31]. The synaptosomes were lysed in 3 mM Tris-HCl, pH 8.5, buffer that
contained a cocktail of protease inhibitors, were centrifuged at 64,200 x g for 15 min, and
the SPM pellet resuspended in 10 mM Tris-HCl, 50 μM MgCl2, 0.32 M sucrose, pH 7.4.
2.3 Capillary HPLC mass spectrometric analysis (LC-MS) of gangliosides
Gangliosides were extracted from SPM samples using the Folch method [32]. Briefly, SPM
samples (50 μl of each with an average protein concentration of 14.8 mg/ml) were made up
to a volume of 250 μl in methanol:water (1:1, v/v) and mixed with 4 ml of
chloroform:methanol (2:1, v/v). After a 25 min incubation, the solutions were centrifuged
(1,000 x g, 5 min). The aqueous (upper) phase was collected while the chloroform layer was
re-extracted three more times with 800 μl methanol:water (1:1, v/v) each time. The aqueous
extracts were combined, dried under vacuum, and stored at −80°C until use. Prior to LC-MS
analysis, samples were resuspended in 500 μl methanol:water (1:1, v/v). HPLC analysis was
performed on a Nano Acquity HPLC system (Waters, Milford, MA). SPM samples and the
mixture of bovine brain gangliosides used as an external standard (5 μL of each) were
initially loaded (45 μL/min, 99% acetonitrile, 1% of 50 mM ammonium acetate buffer, pH
5.6) onto a self-packed reversed phase C8 trap column (Zorbax RX-SB/C8, 5 μm, Agilent
Technologies, Santa Clara, CA) for pre-concentration/desalting. After 3 min, the trap was
switched in-line with an Acquity UPLC HILIC column (BEH-Amide column, 1.7 μm
particle size, 1.0 x 50 mm, Waters). The gangliosides were resolved with an acetonitrile/
ammonium acetate buffer gradient. The total column effluent was introduced into a
SYNAPT G2 hybrid Quadrupole Time of Flight mass spectrometer (Waters). The
instrument was operated in sensitivity mode with a cone voltage of 45 eV and helium was
admitted to the collision (trap) cell. Spectra were acquired at a mass range of 250–3000 m/z.
Time to mass calibration was made with NaI cluster ions acquired under the same
conditions, and lock mass corrected with an auxiliary sprayer presenting the doubly charged
ion (m/z = 554.2614) from leucine enkephalin (YGGFL) peptide. Lock mass spectra were
acquired every 30s. Quantification of each class of gangliosides was performed using
Waters Quanlynx (ver. 4.1) to obtain peak-area data from extracted-ion-plots, targeting
either the singly or doubly charged ions, or both, for each ganglioside species. Mean limits
of detection and quantification for each class of ganglioside were calculated using RMS
signal to noise data (generated by Quanlynx) for each injection.
Linear standard curves for each ganglioside were prepared as follows. Individual
gangliosides from commercial sources were dissolved in DMSO at concentrations ranging
between 1 – 4 mg/mL. The molar concentration of these solutions was determined by the
University of Kansas Nuclear Magnetic Resonance Core laboratory using quantitative NMR
techniques [33]. Nine-point linear standard curves for the gangliosides were generated by
collecting data from triplicate injections of the appropriate serial dilutions (in 1:1
methanol:water) of the primary stock solutions. These standard curves were then used to
calibrate the individual ganglioside abundance in a solution (40 μg/mL solution in 1:1 v/v
methanol:water) made from the dried natural extract of gangliosides GM1, GD1a, GD1b and
GT1b obtained from bovine brains.
Instrument sensitivity was monitored by regularly injecting 5 μL of the bovine-brain
ganglioside mixture and using the calilbration data to attenuate the sample for the effects of
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instrument drift in a ganglioside specific manner. To correct for the effect of signal
attenuation by the sample matrix, known amounts of bovine brain ganglioside mixture were
spiked into three randomly selected SPM extracts, and these extracts were analyzed by LC-
MS. The deficit between the theoretical and observed concentration served as an estimate of
the matrix-dependent signal attenuation for each class of ganglioside.
2.4 Neuronal cell cultures and manipulation of ganglioside levels
Dissociated cortical neuron cultures were established from 18-day old Sprague Dawley
fetuses as described previously [34, 35]. Dissociated neurons were plated at a density of 1.5–
1.75 x 106 cells/dish on 35 mm tissue culture dishes. After 24 h, the medium was replaced
by serum-free Neurobasal™ medium [36]. Greater than 90% of the cells in the primary
cultures were neurons, based on morphological characteristics and confirmation with
immunofluorescent staining for glial fibrillary acidic protein and neuron specific enolase.
Chronic depletion of cellular gangliosides was achieved by treating neurons with D-PDMP,
an inhibitor of ganglioside synthesis [37]. Neurons were treated for 3 days with 10 μM D-
PDMP added to the culture medium on day in vitro (DIV) 6. L-PDMP, the enantiomeric
form of D-PDMP, was used as a negative control for the ganglioside depletion and was
added to the neuronal cultures in the same way as D-PDMP. Changes in the sialic acid levels
of the cell surface gangliosides were achieved through treatment with neuraminidase [25].
The neuraminidase was prepared in Neurobasal™ medium, filtered, and applied to each dish
at 1 unit/ml on DIV 6. The neuraminidase was present in the cultures for 3 days before the
cell collection.
2.5 HPTLC of gangliosides in neuronal membranes
Following exposure of neurons in culture to the agents noted above, the cell culture medium
was removed, the cells washed twice with 200 mM Tris-HCl, pH 7.4, and then lysed in 3
mM Tris-HCl buffer, pH 8.0, containing a cocktail of protease inhibitors. The plasma
membrane-enriched fraction was obtained following centrifugation of the lysate at 10,000 x
g at 4°C for 20 min, and the resuspension of the pellet in 3 mM Tris-HCl, pH 8.0. For the
ganglioside preparation, cell particulate fractions (1 mg protein) were treated the same as for
the ganglioside extraction from SPM samples. All of the upper phases were combined and
KCl was added (final concentration of 0.1 M). The ganglioside-containing extracts were
applied to Sep-Pak C18 cartridges (Sep-Pak 1 cc, 100 mg, Waters) that were pre-washed
three times alternately with 10 volumes of methanol and chloroform/methanol/0.1 M KCl in
water (3:48:47) [38]. Salts and other contaminants were washed from the cartridge matrix
with 10 volumes of water, the gangliosides were eluted with 8 volumes of methanol, dried in
a Speedvac, and re-dissolved in chloroform/methanol/water (2:1:0.1). HPTLC was
performed as described previously [39]. Briefly, the tank was saturated overnight with the
developing solvent chloroform/methanol/water (55:45:10) containing 0.02% CaCl2. Pre-
coated HPTLC plates were first activated by heating at 100 °C for 15 min and then cooled
down to room temperature under desiccation. Ganglioside standards containing a total of 5
μg of 4 major brain gangliosides and the ganglioside samples from the cells were spotted as
7 mm streaks, 3 cm from the edge of the plate. The plate was developed for ~50 min until
the solvent ascended to within 1 cm of the top of the plate. After being completely dried, the
plate was sprayed with a fine mist of resorcinol/HCl/Cu2+ reagent [40] and heated in the
oven at 110°C for 1 hr to allow visualization of the gangliosides. Plates were scanned in a
Kodak Image Station 4000MM PRO (Carestream Health Inc., Rochester NY) using a
colorimetric method at multi-wavelengths between 555 and 700 nm, and the density of each
spot quantified using Carestream Molecular Imaging Software 5.x (Carestream Health Inc.).
Finally, the level of ganglioside GM1 in 20 μg of each particulate sample protein was used
as a general index of membrane-associated gangliosides and was determined by
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immunoblotting using CTXB (300 μg/ml) and procedures identical to those previously
published [30].
2.6 PMCA activity and protein immunoblotting
The activity of PMCA in the particulate fraction was determined by monitoring the Ca2+-
activated generation of Pi from ATP as described previously [30, 31, 34]. For the
immunoblot analyses of proteins, the sample proteins were separated by SDS-PAGE,
transferred to methanol-activated PVDF membranes, and immunoreactivity measured as
described previously [34, 41].
2.7 Data analysis
Statistical significance of differences was assessed using Student’s t test for unpaired
samples, except for the LC/MS estimates of SPM-associated gangliosides in which one-way
ANOVA with post-hoc Tukey-Kramer analysis was applied.
2.8 Co-immunoprecipitation
SPMs containing 1.2 mg protein in 0.32 M sucrose were diluted 1:10 in 50 mM Tris, 50 mM
NaCl, pH 7.4, containing protease inhibitors and phosphatase inhibitors. After centrifugation
at 100,000 x g for 1h to remove the sucrose, the membrane proteins were extracted by
resuspending the pellet in detergent-containing buffer (50 mM Tris, 50 mM NaCl, 0.1%
NP-40, pH 7.4, protease inhibitors and phosphatase inhibitors). The membranes, were frozen
in liquid nitrogen and thawed at 37°C 3–6 times, and were spun at 12,000 x g for 20 min.
The supernatant was collected as the detergent soluble fraction and the starting material of
the co-immunoprecipitation. A preclearing step was performed with 7–10 μg of irrelevant
antibody (mouse IgG, Sigma I8765) for 2h at 4°C and 40 μl Protein A UltraLink™ resin
(Thermo Scientific, 50% slurry). The remaining protein lysate was incubated with 2 μl (2–
10 μg) of pan-PMCA monoclonal antibody overnight at 4°C. The same sample co-incubated
with mouse IgG served as a negative control. The antigen-antibody complexes were passed
through the Protein A UltraLink™ resin and flow-through was collected. After three washes
with the detergent-containing buffer (see above) and one with saline solution (150 mM
NaCl), the resin was resuspended in 100 μl sample buffer (42 mM Tris, 6.7% Glycerol,
2.7% SDS, 0.05% Bromophenol Blue) and boiled. The resuspended eluate was examined for
the yield of PMCA and the presence of gangliosides by immunoblotting using the custom
polyclonal pan-PMCA antibody to detect PMCA, and cholera toxin to detect GM1.
3. Results
3.1 Age-dependent changes in ganglioside content and species in rat brain SPMs
Gangliosides were extracted from SPMs prepared from the individual brains of 6-, 23-, and
34 month old F344/BNF1 rats and were quantified by LC-MS as described under Methods.
Five brain gangliosides, all containing the C18-sphingosine moiety, were detected: GM1,
GD1a, GD1b, GT1b, and GQ1b. Quantification of the first four gangliosides was possible
because their abundance in all samples exceeded their respective limits of quantitation
(ranging between 0.5 and 20 pmol/injection, depending on the species). We were unable to
accurately measure GQ1b because its concentration in all samples, regardless of age, barely
exceeded the limit of detection for that species (7 pmol/injection). The two most abundant
species in terms of the length of the fatty acid chain, i.e., 18:0 (Fig. 1A, n=4) and 20:0 (Fig.
1B, n=4), were detected for GM1, GD1a, GD1b, and GT1b. Two patterns of age-related
change in SPM gangliosides were observed (Fig 1). The abundance of the mono-
sialoganglioside GM1, both C18 and C20 fatty acyl chain lengths, markedly increased with
age (~1.5 fold at 34 months for). In contrast, the levels of the poly-sialogangliosides GD1a,
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GD1b, and GT1b, of both the species with C18 and the C20 fatty acyl chain length,
decreased between 6 and 23 months and were restored to the 6-month level at 34 months.
3.2 Effects of D- and L-PDMP treatment of primary neuronal cultures on neuronal
structure, ganglioside and protein content
To determine whether changes in the levels of endogenous gangliosides in the SPMs might
affect the PMCA activity, we designed experiments in which we manipulated the
endogenous levels of gangliosides in primary neurons. PDMP is a synthetic analog of the
ceramide backbone of gangliosides. The D-threo enantiomer of PDMP is an inhibitor of
UDP-glucose:ceramide glucosyltransferase, the enzyme that is required for the first step in
glycosphingolipid synthesis. The L-threo-PDMP lacks such activity and was used as a
control for the effects of treatment with D-PDMP. To assess whether PDMP caused toxicity
in primary cortical neurons, we treated the cells with either 10 μM D-PDMP or 10 μM L-
PDMP for 3 days as described under Methods. We observed that the untreated cells had a
normal neuronal structure with an intact neurite network, whereas the cells treated with
either enantiomer of PDMP tended to have fewer, shorter, and beaded neurites (Fig. 2A).
We have counted all recognizable neurites in 4 areas of equal size for each of the images we
obtained. The neurites were counted in 4 images of cells per treatment condition. The results
indicated that control cultures had an average 27.0 ± 1.3 neuritic processes per 5.7 cm2 area,
D-PDMP-treated neuronal cultures had 17.7 ± 0.6 processes, and L-PDMP-treated neurons
had 17.4 ± 1.0 processes. Both PDMP-treated neurons had significantly fewer neuritic
processes than the control (p<0.01 for both PDMP treatments) whereas there is no
significant difference between D- and L-PDMP-treated neurons (p=0.82). The effects of
PDMP enantiomers on the morphology of primary neurons observed in our studies were
consistent with the findings reported by others [42, 43]. In addition to the changes in the
morphology of neurons produced by D- or L-PDMP treatment, the total protein content of
neurons treated for 3 days was significantly decreased compared with neurons that were
grown in the absence of exposure to either PDMP enantiomer (n=10, Fig. 2B). Both PDMP
treatments led to a ~21% protein loss, indicating a modest and equivalent neurotoxicity of
the two PDMP enantiomers.
We next examined the effect of D-PDMP on the ganglioside content of the membrane-
enriched particulate fraction from primary neuronal cultures. In the initial studies, we used
the binding of CTXB to GM1 as an index of ganglioside content in neuronal samples. Actin
immunoreactivity was used as the loading control and the ratio of GM1 to actin was used to
quantify the relative levels of gangliosides in the samples. D-PDMP reduced significantly
the ganglioside content (~31%) compared with the untreated control samples (n=4) (Fig. 3A
and 3B). On the other hand, L-PDMP treatment did not alter the GM1 levels significantly
(p=0.46), compared with the untreated neuronal samples. The difference between D- and L-
PDMP in terms of their effects on GM1 levels was also significant (n=4). Furthermore,
when we examined the effects of D-PDMP and L-PDMP treatment on the most abundant
species of gangliosides present in neuronal membranes as revealed by HPTLC analyses, we
determined that D-PDMP caused a greater reduction in the levels of most ganglioside
species when compared with the effect of either L-PDMP or the no-treatment condition (Fig.
3C). The effect of D-PDMP on the combined abundance of the major poly-sialogangliosides
(GD1a, GD1b and GT1b) was approximately equal to that on the mono-sialoganglioside
GM1, and represented an ~38% decrease in the levels of these membrane gangliosides as
compared with neuronal membranes from untreated cells (Fig. 3D). L-PDMP caused no
significant decreases in either GM1 or the combined poly-sialoganglioside content (p=0.75
for GM1; p=0.11 for poly-sialogangliosides) when compared with the no-treatment
condition. And, the differential effect of D-PDMP vs. L-PDMP on ganglioside levels was
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also significant, thus the L-PDMP treatment condition was a good control for the effects of
treatment with the enantiomer D-PDMP.
3.3 Effects of ganglioside depletion on PMCA content and activity of neuronal membranes
Having characterized the effects of the PDMP enantiomers on neuronal membrane
gangliosides, we sought to determine whether decreases in ganglioside content affected
either the levels of PMCA protein associated with neuronal membranes or the activity of this
enzyme. An equivalent amount of protein from each particulate fraction was resolved by
SDS-PAGE and probed with the pan-PMCA antibodies (Fig. 4A). The PMCA to actin ratio
was not statistically different between the membranes obtained from the D-PDMP and those
from neurons treated with L-PDMP. The same was true also for the levels of PMCA in D- or
L-PDMP-treated neurons as compared with those of untreated cells.
We next determined the activity of PMCA in the membrane fractions of neurons treated
with either the D- or L- enantiomers of PDMP. Because cells have several ATPase systems,
we first validated that the majority of the activity measured using our method was from
PMCA by applying the PMCA inhibitor to the assay. Carboxyeosin and lanthanum are
operating as PMCA inhibitors through different mechanisms with carboxyeosin competing
for the ATP binding site and lanthanum for Ca2+. We tested the effect of the combination of
the two inhibitors and determined that at 200 μM carboxyeosin plus 500 μM lanthanum, the
maximal inhibition was 91.3 ± 1.6 %, indicating that the enzyme activity we measured was
primarily due to PMCA. The specific activity of PMCA in neuronal membranes from
untreated cells was 13.13 ± 0.31 nmol Pi•mg−1 protein•min−1, whereas that in membranes
from cells treated with D-PDMP was 26% lower than in the controls (9.70 ± 0.38 nmol
Pi•mg−1 protein•min−1) (Fig. 4B). In contrast to the effects of D-PDMP, L-PDMP had no
statistically significant effect on the PMCA activity when compared with untreated controls
(12.24 ± 0.25 nmol Pi•mg−1 protein•min−1, p=0.06). The differential effect of D-PDMP vs.
L-PDMP on PMCA activity was significant and indicated that gangliosides either promoted
or sustained the activation of PMCA.
We also examined whether the PMCA activator CaM was a major contributor to the
sensitivity of PMCA to ganglioside depletion. The PMCA activity was only marginally
stimulated by the addition of CaM to untreated primary neurons [34] and the D-PDMP-
induced decrease in the activity of PMCA could not be reversed by the addition of 300 nM
exogenous CaM to the assay (data not shown). Finally, to rule out the possibility that D-
PDMP had inactivated PMCA by binding directly to it, we added 10 μM (final
concentration) D-PDMP directly into an assay system set up with cells not previously
treated with D-PDMP. The addition of D-PDMP into the PMCA assay medium had no
effect on the activity of the enzyme, indicating that D-PDMP does not exert a direct effect
on the enzyme (data not shown).
3.4 Neuraminidase-induced conversion of endogenous polysialyl ganlgiosides to GM1 and
effects on PMCA
The treatment of neuronal cultures with D-PDMP decreased the levels of all species of
membrane-associated gangliosides; thus no conclusions could be drawn with respect to any
selective effects on PMCA associated with either mono- or poly-sialogangliosides. Because
of the differential patterns of change in poly- vs. mono-sialogangliosides in SPMs from
older animals, we explored the possible differential sensitivity of the enzyme to mono- vs.
poly-sialogangliosides which might be important in the regulation of the PMCA during the
aging process. To control the level of sialylation of gangliosides in the plasma membrane of
neurons we treated the cells with neuraminidase. This enzyme hydrolyzes the α-glycosidic
bonds between sialic acid and cell surface glycoconjugates [44], thus converting polysialyl
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gangliosides to GM1, a species resistant to neuraminidase-induced cleavage [25, 45].
Neurons in culture were exposed to Clostridium perfringens neuraminidase at a higher
concentration than that employed in previous studies (1 unit/mL) [45] and for a prolonged
period (3 days) in order to compensate for the fact that the incubations were conducted
under non-optimal pH conditions for enzyme activity [46].
Examination of the neuronal cultures by phase contrast microscopy showed that the
neuraminidase-treated primary neurons had darker, thickened neurites when compared with
the untreated cells (Fig. 5). These morphological changes would fit the known induction of
neuritogenesis following neuraminidase treatment [45]. Yet, despite the thickening of
neuritic processes following neuraminidase treatment, the total protein content of
neuraminidase-treated neurons was ~15% less than that of untreated controls (p<0.001,
n=8). With respect to the ganglioside content of neuronal membrane preparations from
neuraminidase-treated neurons, as expected, immunoblot labeling of GM1 with CTXB
revealed that the GM1 to actin ratio in particulates of neuraminidase-treated neurons was
~2.5-fold higher than that in particulates from untreated neurons (Fig. 6A). Quantification of
the ganglioside bands from HPTLC images (Fig. 6B) demonstrated that the major di-
(GD1a, GD1b) and tri-sialogangliosides (GT1b) were reduced by a factor of 2–3 following
exposure of neurons to neuraminidase, while GM1 increased by approximately the same
factor of 2–3 (Fig. 6C, n=3). Commercial preparations of neuraminidase are reported to
catalyze the hydrolysis of the N-acetylneuraminic acid group from GM2 gangliosides [47].
However, we observed only a marginal change in the GM2 level following exposure of
primary cortical neurons to neuraminidase. This might have been due to the generally low
level of expression of GM2 in neurons.
Immunoblot analyses using pan-PMCA antibodies indicated no significant changes in
PMCA levels (PMCA to actin ratios, data not shown) in primary neurons treated with
neuraminidase compared with controls. This suggests, once more, that alterations in
endogenous ganglioside composition of neurons did not affect the PMCA levels in
membranes. On the other hand, neuraminidase treatment did affect the PMCA activity in
neuronal membranes (Fig. 7). Membranes from neurons treated with neuraminidase
exhibited an ~39% decrease in the specific activity of PMCA (8.57 ± 0.64 nmol Pi•mg−1
protein•min−1) as compared with membranes from cultures not exposed to neuraminidase
(13.95 ± 0.65 nmol Pi•mg−1 protein•min−1). The decrease in PMCA activity following
neuraminidase treatment was coincident with an increase in GM1 content and the decreases
in poly-sialogangliosides. The greater reduction in PMCA activity induced by
neuraminidase (39%) as compared with that induced by D-PDMP (26%) might indicate that
PMCA activity in neuronal membranes is up-regulated by poly-sialogangliosides and down-
regulated by GM1.
3.5 The expression of PMCA isoforms in brain SPMs compared with neuronal particulates
The age-related changes in ganglioside content in neurons were observed using SPM
preparations from rat brain, whereas the effects of manipulating ganglioside levels were
determined in particulate fractions from primary neuronal cultures. Since all measurements
of the effects of mono- and poly-sialogangliosides on PMCA activity were obtained using
particulate preparations from primary neuronal cultures, it was important to assess the
similarities in the expression of the four isoforms of PMCA in SPMs from brain and the
particulate fraction from primary neurons. To this end, we assessed the relative levels of
each of the four PMCA isoforms in SPMs vs. neuronal particulates by immunoblot analysis
(Fig. 8). We found that all isoforms were present in both sample types although they were
relatively less abundant in the crude neuronal membrane fraction. This difference in PMCA
abundance was likely related to the higher level of plasma membrane purification in the
Jiang et al. Page 9













SPM fraction vs. the whole cell particulates. Despite the lower enrichment in PMCA in the
cell particulate fraction, all 4 isoforms were present at similar levels proportionately
represented in the two preparations.
3.6 Association of gangliosides with PMCA
To determine if there is any direct interaction between gangliosides and PMCA, we
performed co-immunoprecipitation experiments with a solubilized protein fraction of the
brain SPMs. The SPM protein complexes were extracted and solubilized by using the
nonionic detergent, NP-40, at a low concentration of 0.1% in order to extract the complexes
out of the membranes while maintaining the structures and their possible interacting partners
intact. The majority of PMCA appeared in the detergent soluble fraction whereas GM1
showed an opposite trend (Fig. 9 lanes 1 and 2). Co-immunoprecipitation of PMCA was
carried out using the monoclonal pan-PMCA antibody. Mouse IgG was used as a negative
control. The flow-through and eluate were collected and examined by immunoblotting using
the polyclonal pan PMCA antibody to determine the PMCA yield and the specificity of the
immunoprecipitation (lanes 3–6). In the eluate, in addition to the PMCA band at ~140 kDa,
we observed two broad bands with heavy staining at higher molecular weights (lane 5).
Protein identification via gel electrophoresis followed by Coomassie staining and MS
analysis confirmed that PMCA was also present in those two bands, possibly representing
PMCA aggregates and/or PMCA-interacting complexes. Densitometric measurement of
PMCA bands in the starting material (lane 1) vs. eluate (lane 5), factored by the total volume
of the sample, revealed that 52% of the total PMCA had been immunoprecipitated. There
was virtually no immunoreactivity in the negative control (lane 6). GM1 did not seem to
bind to the PMCA-linked resin and thus appeared in the flow-through (lane 3). No
detectable amount of GM1 was observed in the eluate despite the loading of a larger volume
of the eluate (lane 5). This indicated that GM1 was not interacting with the PMCA proteins
directly. Immunoblots of flow-through and eluate were also run to probe for GD1a by using
an anti-GD1a antibody, and results similar to those with GM1 were obtained (data not
shown), further confirming that gangliosides did not directly associate with the PMCA in
neuronal membranes through tight binding interactions.
4. Discussion
Using a high-resolution and high-sensitivity LC-MS method to assess age-related changes in
the relative abundance of specific gangliosides in rat brain SPMs, we found that the levels of
the major brain gangliosides did change with age and that such changes were different for
the poly-sialogangliosides when compared with those of the mono-sialogangliosides. The
results of our studies pointed to significant decreases in GD1a and GT1b at 23 months of
age, and a significant increase in GM1 content in synaptic membranes at 34 months of age.
All values reported for changes in the content of various ganglioside species in older rats
were compared with those in SPMs from 6 month old rats.
The LC-MS method employed in our studies utilized a trapping strategy to simultaneously
desalt and focus the gangliosides prior to resolving them by HILIC. This approach enabled
each of five major classes of gangliosides (GM1, GD1a, GD1b, GT1b, GQ1b) to be fully
resolved, despite the fact that they are chemically similar amphipathic molecules and that
GD1a and GD1b are isobaric. The high performance mass spectrometry (i.e., mass-
resolution, accuracy, and fragmentation by MSe) afforded substantive molecular speciation
enabling us to differentiate between co-eluting gangliosides and the C18:1 sphingosine
family, as well as between those that differed only in the length of their fatty acyl chains
(18:0 vs. 20:0). We also noted that the use of the limit of quantitation (LoQ) as a measure of
sensitivity was more appropriate than the standard ganglioside quantitative techniques. The
measurement of the worst LoQ (20 pmol/injection for the GM1 with the 18:0 fatty acyl
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chain) was achieved in spite of the fact that this ganglioside co-eluted with the residual
sucrose added during extraction of the SPMs (see supplemental data).
Changes in ganglioside levels during development and aging have been reported previously,
but most of these measures were obtained from homogenates of rat [14], mouse [48], and
human brains [16, 49]. Therefore, it is not clear whether the changes in ganglioside content
reported in previous studies reflect age-related neuronal or glial alterations. In the present
study, we employed a fraction of neuronal SPMs and observed significant increases in the
abundance of GM1 in SPMs from the oldest rats. These findings are consistent with the age-
associated, high density clustering of GM1 at presynaptic terminals reported previously [50].
Our observations showing no age-associated changes in the fatty acid composition of either
the C18:1 or C20:1 sphingosine component of all major brain gangliosides present in rat
synaptosomal fractions are also consistent with those reported previously [51]. The reason
why GD1a and GT1b content was first decreased at 23 mos and restored at 34 mos is
unclear and could be a compensatory mechanism for the neurons at 34 mos to overcome the
effects of lower levels of the poly-sialogangliosides at 23 mos.
Different types of gangliosides have been reported to produce divergent effects on the
activity of PMCA purified from either brain synaptosomes or erythrocyte membranes and
reconstituted into liposomes [12, 13]. In these studies, it was shown that the effects of
gangliosides on the activity of PMCA are related to the number of sialic acid residues
present in the gangliosides, with GD1b stimulating, GM1 reducing, and asialo-GM1
markedly inhibiting the PMCA activity. If changes in the content of endogenous GM1 and
GD1b in SPMs have effects on the activity of membrane-attached PMCA that are similar to
those of exogenously added gangliosides, then we would predict that the age-associated
increases in GM1 and transient decreases in GD1b in rat brain SPMs would lead to an
overall age related reduction in neuronal PMCA activity. To assess the validity of this idea,
we chose to manipulate the total content of endogenous gangliosides as well as the levels of
the various ganglioside species.
We performed two manipulations to alter endogenous ganglioside levels. One was aimed at
suppressing the synthesis of both mono- and poly-sialogangliosides by treating neurons with
D-PDMP. The other was designed to reduce the content of poly-sialogangliosides while
increasing the level of GM1 through treatment of primary neurons with neuraminidase. Both
manipulations decreased the activity of PMCA without having a significant effect on PMCA
protein levels. Both D-PDMP and L-PDMP, as well as the neuraminidase treatments,
induced slight morphological changes in the neuronal cultures and caused similar but small
losses of total protein when treated cultures were compared with untreated controls. But,
whereas D-PDMP inhibited PMCA activity significantly, L-PDMP had no significant effect
on PMCA activity. This selectivity suggests that it is the reduction in overall ganglioside
content in neurons treated with D-PDMP that caused decreases in enzyme activity.
Neuraminidase treatment of primary neurons led to an even greater loss of PMCA activity
than that seen with D-PDMP (39% vs. 26%). As neuraminidase markedly increased GM1
while causing significant decreases in poly-sialogangliosides, it appears that poly-
sialogangliosides facilitate and GM1 reduces PMCA activity. Based on these observations
we suggest that the naturally occurring decreases in the disialo- and trisialo-gangliosides at
23 months of age combined with the increases in GM1 at 34 months of age might both
contribute to the loss of activity of neuronal PMCA during the aging process.
Conclusions about the role of gangliosides in PMCA regulation based on the results of
treatment of neurons with neuraminidase should be tempered by the fact that such enzymatic
treatment would cleave not only sialic acid residues in gangliosides but also sialic acid
residues in glycoproteins. Thus, unlike the D-PDMP treatments that affect only the
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biosynthesis of gangliosides, neuraminidase treatments may potentially alter the
environment of PMCA by changing the structure of both gangliosides and glycoproteins.
Moreover, with both D-PDMP and neuraminidase treatments, gangliosides other than the
ganglio series, such as GD3 and GM3, were also decreased, which could contribute to the
PMCA activity loss. Finally, since all of the studies of neuraminidase and D-PDMP
treatments on PMCA activity were focused on the Ca2+-activated ATP hydrolysis,
additional studies are planned to also measure the effects of such manipulations on ATP-
dependent Ca2+ transport in neuronal preparations.
The mechanisms underlying the modulation of PMCA by gangliosides remain
undetermined. Gangliosides may modulate PMCA function either through direct interaction
with the enzyme or through a broader effect on the biophysical properties of the membrane
lipid bilayer. Previous studies of the effects of adding exogenous gangliosides to liposome-
reconstituted preparations of PMCA indicated that direct interactions between gangliosides
and the protein do occur [12]. However, our results from co-immunoprecipitation studies
revealed that endogenous gangliosides in SPMs may not interact directly with PMCA or that
the affinity of such binding interactions is low and the binding is readily reversible. This
finding is consistent with our assumption that gangliosides, residing in the outer leaflet of
the membrane with their head-groups extending toward the extracellular medium, may have
transient, possibly low affinity interactions with the PMCA extracellular domain or they
may have an indirect effect on lipid bilayer organization. It should be noted that 70% of the
mass of the PMCA protein and nearly all of the functional domains are on the cytoplasmic
side of the plasma membrane [52].
With regard to the effects of gangliosides on PMCA that may be produced through changes
in the overall membrane structure, it is important to point out that an ordered lipid
environment, such as that in raft domains, increases the PMCA activity [30, 34, 53]. In the
present study, neither D-PDMP nor neuraminidase treatments altered the membrane
cholesterol levels (data not shown). Thus the effects of the treatments could not be ascribed
to cholesterol depletion or enrichment of the membranes. It has been suggested that the large
hydrophilic head-groups of gangliosides may help to form and stabilize membrane lipid
domains that exhibit a positive curvature [54]. Therefore, changes in the carbohydrate units
could affect the membrane curvature and intermolecular packing, thereby altering the three
dimensional structure of membrane proteins and leading to either their activation or
inhibition [54, 55]. Also, the geometry of the gangliosides, which is determined by the size
of the head-groups, can modulate the fluidity of the membrane lipid core [54] and thus affect
the activity of membrane-associated enzymes. A mechanistic resolution of the various
alternatives must await more definitive biophysical measurements of ganglioside effects on
membrane structure. The results of such studies might shed light on the mechanisms
underlying the effects of compositional changes in gangliosides and their relationship to the
loss of PMCA activity in aging brain membranes.
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CTXB cholera toxin subunit B
D/L-PDMP D/L-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol • HCI
HPLC high performance liquid chromatography
HPTLC high performance thin layer chromatography
LC-MS liquid chromatography-mass spectrometry
MS mass spectrometry
NCX Na+/Ca2+ exchanger
PMCA plasma membrane Ca2+-ATPase
[Ca2+]I intracellular calcium concentration
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• Ganglioside content was significantly altered with advancing age
• Ganglioside depletion by D-PDMP decreased the PMCA activity significantly
• Neuraminidase treatment decreased poly- and increased mono-sialogangliosides
• Neuraminidase treatment markedly decreased PMCA activity
• The endogenous ganglioside content and species affected PMCA activity in
neurons
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Fig. 1. Alterations in SPM gangliosides with aging
Gangliosides were extracted from SPMs isolated from brains of F344/BNF1 rats at the ages
of 6, 23, and 34 mos and were quantified by HPLC-MS. The 2 most abundant constituents
for each ganglioside species containing C18-spingosine but varying in the fatty acyl chain
are presented. (A) Ganglioside species with C18-sphingosine and C18 fatty acyl chains; (B)
Ganglioside species with C18-sphingosine and C20 fatty acyl chains. Data are means ±
SEM from 4 preparations of SPMs per age. Statistical analysis was performed by one-way
ANOVA with post-hoc Tukey-Kramer. * indicates p<0.05, ** p<0.01, *** p<0.001.
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Fig. 2. Effects of D- and L-PDMP on neuronal cultures
(A) Representative phase contrast images of primary cortical neurons with no treatment
(control) or treated with either 10 μM D-PDMP or L-PDMP for 3 days. Images were taken
at a 20x magnification. A box used to count the neuritic processes is shown as an example
on each image. The intact neurites in 4 boxes from each image obtained from 4 cultures per
treatment condition were counted and the average number calculated and reported in the
text. (B) Effects of D- and L-PDMP on protein levels in neuronal cultures. After a 3-day
treatment with PDMP, cells were collected and lysed, and the total protein/dish was
determined by the bicinchoninic acid assay. Data are means ± SEM obtained from 10
experiments using different culture preparations. Statistical evaluation of the differences
between control and treated cultures was determined using Student’s t-test for unpaired
samples.
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Fig. 3. Effects of PDMP treatments on GM1 levels
(A) Immunoblot analysis of GM1 following exposure to 10 μM D- or L-PDMP. Twenty
micrograms of protein from cell particulate fractions were loaded to each gel lane, and GM1
was detected via CTXB. Anti-actin antibody was used at 1:1000 dilution. A representative
immunoblot from 4 independent experiments with similar results is shown. (B)
Densitometric analyses of the levels of GM1 in particulate fractions normalized to actin as a
loading control. Data represent means ± SEM from 4 experiments using different cultures.
(C) Ganglioside profiling by HPTLC. Gangliosides extracted from particulate fractions
containing 1mg protein were separated on an HPTLC plate. (D) Quantification of HPTLC
images. Data are presented as means ± SEM from 5 experiments using different cultures.
The total levels of GM1 vs. the combined content of polysialogangliosides (GD1a, GD1b,
GT1b) expressed in the control, D-PDMP- and L-PDMP-treated neurons are shown.
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Fig. 4. Effects of ganglioside depletion on PMCA content and activity
(A) Immunoblot analysis of PMCA following exposure to 10 μM D- or L-PDMP. Twenty
micrograms of protein from cell particulate fractions were loaded to each gel lane. Anti-pan-
PMCA and anti-actin antibodies were used at 1:1000 dilution. A representative immunoblot
from 4 independent experiments with similar results is shown. (B) The specific activity of
PMCA in neuronal particulate fractions (9 μg protein) from control cultures and D- or L-
PDMP treated cultures was assayed. The data represent means ± SEM from 4 different cell
preparations.
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Fig. 5. Effects of neuraminidase on cultured neurons
Phase contrast images of primary cortical neurons with no treatment (control) or treated with
neuraminidase at 1 unit/mL for 3 days were taken at a 20x magnification.
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Fig. 6. Levels of GM1 and PMCA after exposure to neuraminidase
(A) Mean ratios of GM1 to actin after neuraminidase treatment. The results are from 4
experiments using different cultures. (B) Representative HPTLC image showing the effect
of neuraminidase exposure on poly-sialoganglioside levels (n= 3 cultures). (C)
Densitometric analysis of HPTLC images from 3 different cell preparations. Data are
presented as means ± SEM of GM1 vs. the combined content of poly-sialogangliosides.
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Fig. 7. Effects of neuraminidase treatment on PMCA activity
The specific activity of PMCA was measured in particulate fractions from control or
neuraminidase-treated neurons. The data shown are the means ± SEM from 4 different cell
preparations.
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Fig. 8. PMCA isoforms in SPMs and neuronal particulates
Fifteen micrograms of protein from either SPMs or cell particulates were loaded to each gel
lane for probing the levels of pan PMCA and the 4 isoforms. The dilution of each primary
antibody is: 1:1000 for anti-pan-PMCA, 1:400 for anti-PMCA1, PMCA3, and PMCA4, and
1:2000 for anti-PMCA2.
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Fig. 9. Test for direct interaction between PMCA and gangliosides
The membrane proteins were extracted from SPMs and solubilized by 0.1% NP-40. Co-
immunoprecipitation was performed by co-incubation of the detergent soluble fraction with
monoclonal pan PMCA antibody and Protein A UltraLink™ resin (see Methods). Flow-
through and eluate were both collected and analyzed via immunoblotting for the yield of
PMCA using polyclonal pan PMCA antibody (1:400 dilution) and the detection of GM1
using cholera toxin. Lane 1: detergent soluble fraction, 5 μg protein loading (3.32 μl); Lane
2: detergent insoluble fraction, 5 μg (3.10 μl); Lane 3: flow through, 12 μg (7.64 μl); Lane
4: flow through of the negative control, 12 μg (8.69 μl); Lane 5: eluate, 8 μl for PMCA and
40 μl for GM1 probing; Lane 6: eluate of the negative control, 8 μl for PMCA and 40 μl for
GM1.
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